Tokyo, Japan

Makoto Okazaki

This inventor holds 4 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Chugai Seiyaku Kabushiki Kaisha. Active years: 2006-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Makoto Okazaki. Retrieved from https://idiyas.com/inventor/makoto-okazaki-n5iadafx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 75.0

 

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Shizuoka, JP (2013 - 2015)
  • Tokyo, JP (2006 - 2016)

Company Filing History:


Years Active: 2006-2016

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Inventor Makoto Okazaki: Pioneering Innovations in Parathyroid Hormone Research**

Introduction

Makoto Okazaki, based in Tokyo, Japan, is a notable inventor recognized for his significant contributions to the field of biochemistry, particularly in parathyroid hormone analogs. With a total of four patents to his name, Okazaki continues to spearhead advancements aimed at improving therapeutic approaches for hormone deficiencies.

Latest Patents

Among his latest inventions is a patent for "Parathyroid hormone analogs and uses thereof." This innovative work discloses two novel parathyroid hormone (PTH) analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, which demonstrate long-acting activity at the PTH receptor. These polypeptides are particularly advantageous for treating conditions like hypoparathyroidism, where sustained action is necessary. Additionally, the patent outlines methods for creating these analog polypeptides, paving the way for enhanced treatment options.

Another noteworthy patent by Okazaki is centered around "Screening methods using G-protein coupled receptors and related compositions." This invention introduces screening methods for G-protein coupled receptors (GPCRs) and reveals that the affinity of a receptor agonist for a GPCR—such as the parathyroid hormone receptor—is correlated with the duration of the agonist’s effectiveness, independent of its pharmacokinetic properties. The invention also includes PTH- and PTHrP-derived polypeptides, further contributing to the field's body of knowledge.

Career Highlights

Throughout his career, Makoto Okazaki has worked at esteemed institutions such as The General Hospital Corporation and Chugai Pharmaceutical Co., where he has collaborated on key projects that underline his expertise in hormone research. His work remains pivotal in the effort to discover effective treatments for hormonal imbalances.

Collaborations

Okazaki has been fortunate to collaborate with prominent figures in the field, including Thomas J. Gardella and John T. Potts, Jr. These partnerships have not only enriched his research endeavors but also fostered an environment where knowledge and innovation can thrive.

Conclusion

Makoto Okazaki's contributions to the field of parathyroid hormone research through his patents underscore the importance of innovative approaches in medicine. His work not only opens new avenues for treatment but also illustrates the significant role of inventors in advancing scientific understanding and enhancing patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…